Clinical Pharmacokinetics of Lansoprazole
Authors:
- 1 June 1995
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 28 (6) , 458-470
Abstract
Lansoprazole, a benzimidazole derivative with antisecretory and antiulcer activities, inhibits the acid pump activity at the final stage of the enzyme process and therefore reduces the acid secretion...Keywords
This publication has 21 references indexed in Scilit:
- Oxidative metabolism of lansoprazole by human liver cytochromes P450.Molecular Pharmacology, 1995
- Lansoprazole does not affect the bioavailability of oral contraceptives.British Journal of Clinical Pharmacology, 1994
- [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].1994
- Duodenal bacterial overgrowth during treatment in outpatients with omeprazole.Gut, 1994
- Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine.Gut, 1993
- [Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial].1993
- Influence of lansoprazole treatment on diazepam plasma concentrationsClinical Pharmacology & Therapeutics, 1992
- High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urineJournal of Chromatography B: Biomedical Sciences and Applications, 1991
- Dose‐related healing of duodenal ulcer with the proton pump inhibitor lansoprazoleAlimentary Pharmacology & Therapeutics, 1991
- Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells.The Journal of Pharmacology and Experimental Therapeutics, 1990